Kenneth Cornetta

List of Publications by Year in Descending Order

38 papers	1,662 citations	13 h-index	40 g-index
41 ext. papers	1,866 ext. citations	6.5 avg, IF	3.74 L-index

#	Paper	IF	Citations
38	Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. *Blood*, **2021**, 138, 1304-1316	2.2	8
37	AAV Joins the Rank of Genotoxic Vectors. *Molecular Therapy*, **2021**, 29, 418-419	11.7	9
36	Use of a Novel Trigger Tool to Identify Palliative Care Needs in Surgical Patients at a National Referral Hospital in Kenya: A Pilot Study. *Journal of Palliative Medicine*, **2021**, 24, 1455-1460	2.2	
35	Replication-Competent Lentivirus Analysis of Vector-Transduced T Cell Products Used in Cancer Immunotherapy Clinical Trials. *Methods in Molecular Biology*, **2020**, 2086, 181-194	1.4	
34	The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community. *Human Gene Therapy*, **2020**, 31, 145-150	4.8	1
33	Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies. *Cytotherapy*, **2020**, 22, 669-676	4.8	1
32	The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state. *Journal of Clinical and Translational Science*, **2020**, 5, e33	0.4	
31	Gene Transfer to HSCs: Finding the Leukemia in Murine Leukemia Viruses. *Molecular Therapy*, **2019**, 27, 1072-1073	11.7	
30	Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort. *Blood*, **2019**, 134, 3345-3345	2.2	11
29	IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. *Clinical Cancer Research*, **2019**, 25, 1000-1011	12.9	7
28	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. *Molecular Therapy*, **2018**, 26, 280-288	11.7	53
27	Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy. *Molecular Therapy*, **2018**, 26, 2715-2716	11.7	5
26	Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. *Molecular Therapy - Methods and Clinical Development*, **2018**, 10, 371-378	6.4	15
25	Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. *Molecular Therapy - Methods and Clinical Development*, **2014**, 1, 11	6.4	41
24	Design and Potential of Non-Integrating Lentiviral Vectors. *Biomedicines*, **2014**, 2, 14-35	4.8	25
23	Development and Evaluation of Quality Metrics for Bioinformatics Analysis of Viral Insertion Site Data Generated Using High Throughput Sequencing. *Biomedicines*, **2014**, 2, 195-210	4.8	0
22	Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. *Molecular Therapy*, **2014**, 22, 607-622	11.7	64

21	Transgenic sheep generated by lentiviral vectors: safety and integration analysis of surrogates and their offspring. *Transgenic Research*, **2013**, 22, 737-45	3.3	8
20	Balancing personalized medicine and personalized care. *Academic Medicine*, **2013**, 88, 309-13	3.9	52
19	Replication-competent lentivirus analysis of clinical grade vector products. *Molecular Therapy*, **2011**, 19, 557-66	11.7	40
18	De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A. *Blood*, **2010**, 116, 2198-2198	2.2	1
17	Mutation In Erythroid Specific Transcription Factor KLF1 Causes Hereditary Spherocytosis In the Nan (Neonatal Anemia) Hemolytic Anemia Mouse Model. *Blood*, **2010**, 116, 3217-3217	2.2	0
16	The National Gene Vector Biorepository's Pharm/Tox Database. *Molecular Therapy*, **2009**, 17, 582-4	11.7	1
15	Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. *Journal of General Virology*, **2008**, 89, 2611-2621	4.9	14
14	Production of retroviral vectors for clinical use. *Methods in Molecular Biology*, **2008**, 433, 17-32	1.4	8
13	Cyclosporine Versus Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis after Matched Related and Unrelated Minimal Intensity Allotransplantation.. *Blood*, **2007**, 110, 5014-5014	2.2	
12	Biased Engraftment of Retrovirus-Transduced Marrow in Murine X-CGD Following Submyeloablative Conditioning.. *Blood*, **2006**, 108, 3285-3285	2.2	
11	Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). *Biology of Blood and Marrow Transplantation*, **2005**, 11, 149-60	4.7	118
10	Reconstitution of Neutrophil NADPH Oxidase Activity in Murine X-CGD Following Transplantation of Retrovirus-Transduced Marrow: Potential Impact of Submyeloablative Conditioning.. *Blood*, **2005**, 106, 3050-3050	2.2	
9	Regulatory issues in human gene therapy. *Blood Cells, Molecules, and Diseases*, **2003**, 31, 51-6	2.1	5
8	Regulatory issues for clinical gene therapy trials. *Human Gene Therapy*, **2002**, 13, 1143-9	4.8	17
7	Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. *British Journal of Haematology*, **1998**, 102, 759-67	4.5	35
6	Retroviral gene therapy in hematopoietic diseases. *Journal of Clinical Apheresis*, **1997**, 12, 187-93	3.2	3
5	Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. *Cancer*, **1997**, 79, 1605-10	6.4	63
4	Retroviral mediated gene transfer in chronic myelogenous leukaemia. *British Journal of Haematology*, **1994**, 87, 308-16	4.5	9

3	Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *New England Journal of Medicine*, **1990**, 323, 570-8	59.2	1042
2	Safety of Retroviral Vectors: Regulatory and Technical Considerations277-288		2
1	Murine Leukemia VirusBased Retroviral Vectors7-17		1